Arovella Completes $4.57M Placement & Launches $1.5M SPP
Filed with ASX · · 4 pages · English
• The capital raised will be used to fund Arovella’s cell therapy programs including the development of its invariant Natural Killer T (iNKT) Cell Therapy Platform and novel DKK1- peptide targeting monoclonal antibody for cancer treatment PERTH, AUSTRALIA 24 January 2022:Arovella Therapeutics Limited (Company) (ASX: ALA), a biotechnology company focused on developing its invariant Natural Killer T
Arovella Therapeutics Limited on 6ix
Story so far
Earlier from Arovella Therapeutics
- AGM FY21 Presentation
- Arovella licences novel monoclonal antibody from MD Anderson
- Chile Ministry of Health Approval Granted for ZolpiMist
- GM presentation
- Dr Reuben Benjamin Appointed to SUDA iNKT Cell Therapy SAB
Later from Arovella Therapeutics
- Investor Presentation
- Arovella SPP Closed early over subscribed
- Update - Proposed issue of securities - ALA
- Application for quotation of securities - ALA
- Arovella Therapeutics: Proposed issue of securities - ALA
Follow Arovella Therapeutics into a list and get an email when it puts out news.
Follow Arovella Therapeutics